Navigation Links
Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
Date:5/11/2009

NANTONG CITY, China, May 11 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") is pleased to announce that it has received approval from the Chinese State Food and Drug Administration (SFDA) to manufacture and market its formulation of Perindopril, an anti-hypertension drug.

Perindopril, used alone or in combination with other medications to treat high blood pressure, is the latest generation of a class of medications called angiotensin-converting enzyme (ACE) inhibitors. It supports circulation by preventing the production of chemicals that occur naturally in the body but constrict blood vessels.

As the first Chinese producer of Perindopril, Sinobiopharma comes to market with significant competitive advantages, including lower cost active pharmaceutical ingredients (API), and being the first in the world to offer capsule formulation, which is not only easier to swallow, but also has greater efficacy and reduced side effects compared to earlier versions of the drug. Prior to SFDA approval of Sinobiopharma's version, Servier (France) was the only firm to market Perindopril in China. Perindopril completed clinical trials in September 2007.

High blood pressure is a leading cause of stroke, heart attack and kidney failure; it affects an estimated one billion people worldwide. In China, the incidence of cardiovascular and cerebrovascular diseases is on the rise, costing patients approximately RMB 300 billion (US $37 billion) in medical expenses each year. Of this amount, some RMB 30 billion (US $3.7 billion) is spent directly on the treatment of hypertension, according to China's Ministry of Health.

High blood pressure affects nearly one in five Chinese adults during their lifetime, according to the State Council of China.

"SFDA approval of Sinobiopharma's formulation of Perindopril strengthens our product portfolio in keeping with our strategy of focusing on first-to-market generic and innovative drugs," says Lequn Huang, Company President and CEO.

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

    Contacts:
    Sinobiopharma, Inc.
    Investor Relations
    1-877-568-0188

FORWARD-LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward-looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
2. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
3. Sinobiopharma, Inc. Appoints New Director of Marketing
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
6. Sinobiopharma Secures Rights to Seven Key Patents
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Berkeley, CA (PRWEB) , ... January 19, 2017 ... ... the delivery of product vigilance software to leading biopharmaceutical and medical device manufacturers ... Mail is a fully 21 CFR Part 11-compliant email client designed to provide ...
(Date:1/19/2017)...  ArmaGen, Inc., today announced that it has ... executive officer, as well as a member of ... more than 17 years of executive management experience ... and pharmaceuticals. "Mathias is a ... skillset necessary to lead ArmaGen to its next ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... of Health (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading ... grant applications subject to the existing policy. AMIA recommended that NIH earmark funding ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type of ... growth is accounted to two main factors. The first is the amazing customer ... vendors supplying FireflySci products all around the world. , 2016 was a tremendous sales ...
Breaking Biology Technology:
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much more ... or starting the engine. Continental will demonstrate the intelligence ... Las Vegas . Through the combination of the ... Entry) and biometric elements, the international technology company is ... personalization and authentication. "The integration of biometric ...
(Date:12/8/2016)... PUNE, India , Dec. 8, 2016 Market Research ... and Service Market. The global Mobile Biometric Security and Service Market ... period 2016 to 2022. Market Highlights: ... , , ... fast pace due to the increasing need of authentication and security ...
Breaking Biology News(10 mins):